NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $4.23 -0.03 (-0.70%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Fennec Pharmaceuticals Stock (NASDAQ:FENC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.14▼$4.3050-Day Range$4.19▼$5.5652-Week Range$3.98▼$11.92Volume97,618 shsAverage Volume113,026 shsMarket Capitalization$116.03 millionP/E RatioN/ADividend YieldN/APrice Target$13.67Consensus RatingBuy Company OverviewFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Fennec Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks41st Percentile Overall ScoreFENC MarketRank™: Fennec Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 736th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-37.50% Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to decrease by -37.50% in the coming year, from $0.08 to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -42.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -42.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Fennec Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.76% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.76% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.11 News SentimentFennec Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,856.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FENC Stock News HeadlinesInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of StockNovember 5, 2024 | insidertrades.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call TranscriptNovember 11 at 11:11 AM | msn.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 12, 2024 | Colonial Metals (Ad)Fennec Pharmaceuticals (NASDAQ:FENC) Given "Outperform" Rating at WedbushNovember 11 at 4:25 AM | americanbankingnews.comFennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call TranscriptNovember 9 at 11:01 PM | seekingalpha.comFennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 9 at 2:59 AM | finance.yahoo.comFennec Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 9 at 2:59 AM | markets.businessinsider.comFennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comSee More Headlines FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 on January 1st, 2024. Since then, FENC stock has decreased by 62.3% and is now trading at $4.23. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by $0.26. The business earned $7.26 million during the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative trailing twelve-month return on equity of 53.38%. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/13/2024Today11/12/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+222.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio53.00 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins-2.30% Pretax Margin5.58% Return on Equity-53.38% Return on Assets-2.13% Debt Debt-to-Equity Ratio9.86 Current Ratio8.02 Quick Ratio7.75 Sales & Book Value Annual Sales$21.25 million Price / Sales5.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-9.86Miscellaneous Outstanding Shares27,430,000Free Float24,416,000Market Cap$116.30 million OptionableOptionable Beta0.27 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:FENC) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.